Market Research Logo

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 15, 17, 1, 67 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Idiopathic Pulmonary Fibrosis - Overview
Idiopathic Pulmonary Fibrosis - Therapeutics Development
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
Idiopathic Pulmonary Fibrosis - Drug Profiles
Idiopathic Pulmonary Fibrosis - Dormant Projects
Idiopathic Pulmonary Fibrosis - Discontinued Products
Idiopathic Pulmonary Fibrosis - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2018
Table 2: Number of Products under Development by Companies, H1 2018
Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 7: Number of Products under Development by Universities/Institutes, H1 2018
Table 8: Products under Development by Companies, H1 2018
Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Table 14: Products under Development by Universities/Institutes, H1 2018
Table 15: Number of Products by Stage and Target, H1 2018
Table 16: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Table 17: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Table 18: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Table 19: Number of Products by Stage and Mechanism of Action, H1 2018
Table 20: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Table 21: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Table 22: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Table 23: Number of Products by Stage and Route of Administration, H1 2018
Table 24: Number of Products by Stage and Molecule Type, H1 2018
Table 25: Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2018
Table 26: Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2018
Table 27: Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H1 2018
Table 28: Idiopathic Pulmonary Fibrosis - Pipeline by Allinky Biopharma, H1 2018
Table 29: Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H1 2018
Table 30: Idiopathic Pulmonary Fibrosis - Pipeline by apceth Biopharma GmbH, H1 2018
Table 31: Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Corp, H1 2018
Table 32: Idiopathic Pulmonary Fibrosis - Pipeline by BerGenBio ASA, H1 2018
Table 33: Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H1 2018
Table 34: Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corp, H1 2018
Table 35: Idiopathic Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Table 36: Idiopathic Pulmonary Fibrosis - Pipeline by BreStem Therapeutics Inc, H1 2018
Table 37: Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Co, H1 2018
Table 38: Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corp, H1 2018
Table 39: Idiopathic Pulmonary Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2018
Table 40: Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd, H1 2018
Table 41: Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Ltd, H1 2018
Table 42: Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Table 43: Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen Inc, H1 2018
Table 44: Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H1 2018
Table 45: Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2018
Table 46: Idiopathic Pulmonary Fibrosis - Pipeline by Galecto Biotech AB, H1 2018
Table 47: Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex SA, H1 2018
Table 48: Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2018
Table 49: Idiopathic Pulmonary Fibrosis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
Table 50: Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics Inc, H1 2018
Table 51: Idiopathic Pulmonary Fibrosis - Pipeline by iBio Inc, H1 2018
Table 52: Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H1 2018
Table 53: Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2018
Table 54: Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corp LLC, H1 2018
Table 55: Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt Ltd, H1 2018
Table 56: Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Table 57: Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H1 2018
Table 58: Idiopathic Pulmonary Fibrosis - Pipeline by Medicenna Therapeutics Corp, H1 2018
Table 59: Idiopathic Pulmonary Fibrosis - Pipeline by Merck & Co Inc, H1 2018
Table 60: Idiopathic Pulmonary Fibrosis - Pipeline by Miragen Therapeutics Inc, H1 2018
Table 61: Idiopathic Pulmonary Fibrosis - Pipeline by Mission Therapeutics Ltd, H1 2018
Table 62: Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix Inc, H1 2018
Table 63: Idiopathic Pulmonary Fibrosis - Pipeline by Novartis AG, H1 2018
Table 64: Idiopathic Pulmonary Fibrosis - Pipeline by Nuevolution AB, H1 2018
Table 65: Idiopathic Pulmonary Fibrosis - Pipeline by Nuformix Plc, H1 2018
Table 66: Idiopathic Pulmonary Fibrosis - Pipeline by OliX Pharmaceuticals Inc, H1 2018
Table 67: Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Ltd, H1 2018
Table 68: Idiopathic Pulmonary Fibrosis - Pipeline by Promedior Inc, H1 2018
Table 69: Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2018
Table 70: Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix Inc, H1 2018
Table 71: Idiopathic Pulmonary Fibrosis - Pipeline by Re-Pharm Ltd, H1 2018
Table 72: Idiopathic Pulmonary Fibrosis - Pipeline by Redx Pharma Plc, H1 2018
Table 73: Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H1 2018
Table 74: Idiopathic Pulmonary Fibrosis - Pipeline by Reviva Pharmaceuticals Inc, H1 2018
Table 75: Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc, H1 2018
Table 76: Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma LLC, H1 2018
Table 77: Idiopathic Pulmonary Fibrosis - Pipeline by Samumed LLC, H1 2018
Table 78: Idiopathic Pulmonary Fibrosis - Pipeline by Shionogi & Co Ltd, H1 2018
Table 79: Idiopathic Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics Inc, H1 2018
Table 80: Idiopathic Pulmonary Fibrosis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018
Table 81: Idiopathic Pulmonary Fibrosis - Pipeline by Telocyte LLC, H1 2018
Table 82: Idiopathic Pulmonary Fibrosis - Pipeline by Therabron Therapeutics Inc, H1 2018
Table 83: Idiopathic Pulmonary Fibrosis - Pipeline by Unity Biotechnology Inc, H1 2018
Table 84: Idiopathic Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H1 2018
Table 85: Idiopathic Pulmonary Fibrosis - Pipeline by X-Rx Inc, H1 2018
Table 86: Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corp, H1 2018
Table 87: Idiopathic Pulmonary Fibrosis - Pipeline by Zai Lab Ltd, H1 2018
Table 88: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018
Table 89: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Table 90: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..2), H1 2018
Table 91: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..3), H1 2018
Table 92: Idiopathic Pulmonary Fibrosis - Discontinued Products, H1 2018
List of Figures
Figure 1: Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2018
Figure 2: Number of Products under Development by Companies, H1 2018
Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
Figure 4: Number of Products by Top 10 Targets, H1 2018
Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Figure 8: Number of Products by Routes of Administration, H1 2018
Figure 9: Number of Products by Stage and Routes of Administration, H1 2018
Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report